EmeraMedEmeraMed Ltd is a biotechnology firm developing the lipophilic, blood-brain-barrier passing metal chelator and antioxidant Irminix® (Code: NBMI, INN: Emeramide).

COPDA Phase 2a clinical trial is ongoing for the treatment of COPD and completed in May 2018.

Mercury poisoningThe Company has Orphan Drug Designation for the Prevention and Treatment of Mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed.

Other conditionsPreclinical studies ongoing for other indications.

Early access/Individual Patient treatments:  There are a growing number of approvals and shippings to Switzerland, Germany, Austria, New Zealand, UK, Lebanon and the USA  for Individual Patient use. For more information – please click above.

Subscribe To Our Mailing List: (* indicates required)

Email Format